Ibandronic acid: Difference between revisions
CSV import |
CSV import Tag: Removed redirect |
||
| Line 1: | Line 1: | ||
{{Short description|A bisphosphonate medication used to treat osteoporosis}} | |||
[[File:Ibandronic_acid.svg|Chemical structure of Ibandronic acid|thumb|right]] | |||
'''Ibandronic acid''', also known as '''ibandronate''', is a [[bisphosphonate]] medication primarily used in the treatment and prevention of [[osteoporosis]] in postmenopausal women. It is also used to treat [[bone metastases]] and to reduce [[hypercalcemia]] associated with [[malignancy]]. | |||
==Mechanism of Action== | |||
Ibandronic acid works by inhibiting [[osteoclast]]-mediated bone resorption. Osteoclasts are cells that break down bone tissue, and their activity is increased in conditions like osteoporosis and bone metastases. By binding to [[hydroxyapatite]] in bone, ibandronic acid reduces the activity and number of osteoclasts, leading to decreased bone turnover and increased bone mineral density. | |||
==Pharmacokinetics== | |||
Ibandronic acid is administered either orally or intravenously. When taken orally, it has a low bioavailability of about 0.6% due to poor absorption in the gastrointestinal tract. It is important to take the oral form on an empty stomach to maximize absorption. The drug is rapidly distributed to bone tissue, where it exerts its effects. It is not metabolized and is excreted unchanged in the urine. | |||
==Clinical Uses== | |||
===Osteoporosis=== | |||
Ibandronic acid is used to prevent and treat osteoporosis in postmenopausal women. It helps to increase bone mineral density and reduce the risk of [[vertebral fractures]]. | |||
===Bone Metastases=== | |||
In patients with breast cancer and other malignancies that have spread to the bone, ibandronic acid is used to manage bone pain and reduce the risk of skeletal-related events such as fractures. | |||
===Hypercalcemia of Malignancy=== | |||
Ibandronic acid is effective in reducing elevated calcium levels in the blood associated with cancer, a condition known as hypercalcemia of malignancy. | |||
==Administration== | |||
Ibandronic acid can be administered orally in tablet form or as an intravenous injection. The oral form is typically taken once a month, while the intravenous form may be given every three months. | |||
==Side Effects== | |||
Common side effects of ibandronic acid include gastrointestinal issues such as [[dyspepsia]], [[nausea]], and [[diarrhea]]. Intravenous administration may cause flu-like symptoms. Rare but serious side effects include [[osteonecrosis of the jaw]] and atypical femoral fractures. | |||
==Precautions== | |||
Patients with severe renal impairment should use ibandronic acid with caution, as it is primarily excreted by the kidneys. Adequate intake of calcium and vitamin D is recommended during treatment. | |||
==Related pages== | |||
* [[Bisphosphonate]] | |||
* [[Osteoporosis]] | |||
* [[Bone metastasis]] | |||
* [[Hypercalcemia]] | |||
[[Category:Bisphosphonates]] | |||
[[Category:Osteoporosis]] | |||
[[Category:Bone disorders]] | |||
Latest revision as of 21:37, 4 March 2025
A bisphosphonate medication used to treat osteoporosis
Ibandronic acid, also known as ibandronate, is a bisphosphonate medication primarily used in the treatment and prevention of osteoporosis in postmenopausal women. It is also used to treat bone metastases and to reduce hypercalcemia associated with malignancy.
Mechanism of Action[edit]
Ibandronic acid works by inhibiting osteoclast-mediated bone resorption. Osteoclasts are cells that break down bone tissue, and their activity is increased in conditions like osteoporosis and bone metastases. By binding to hydroxyapatite in bone, ibandronic acid reduces the activity and number of osteoclasts, leading to decreased bone turnover and increased bone mineral density.
Pharmacokinetics[edit]
Ibandronic acid is administered either orally or intravenously. When taken orally, it has a low bioavailability of about 0.6% due to poor absorption in the gastrointestinal tract. It is important to take the oral form on an empty stomach to maximize absorption. The drug is rapidly distributed to bone tissue, where it exerts its effects. It is not metabolized and is excreted unchanged in the urine.
Clinical Uses[edit]
Osteoporosis[edit]
Ibandronic acid is used to prevent and treat osteoporosis in postmenopausal women. It helps to increase bone mineral density and reduce the risk of vertebral fractures.
Bone Metastases[edit]
In patients with breast cancer and other malignancies that have spread to the bone, ibandronic acid is used to manage bone pain and reduce the risk of skeletal-related events such as fractures.
Hypercalcemia of Malignancy[edit]
Ibandronic acid is effective in reducing elevated calcium levels in the blood associated with cancer, a condition known as hypercalcemia of malignancy.
Administration[edit]
Ibandronic acid can be administered orally in tablet form or as an intravenous injection. The oral form is typically taken once a month, while the intravenous form may be given every three months.
Side Effects[edit]
Common side effects of ibandronic acid include gastrointestinal issues such as dyspepsia, nausea, and diarrhea. Intravenous administration may cause flu-like symptoms. Rare but serious side effects include osteonecrosis of the jaw and atypical femoral fractures.
Precautions[edit]
Patients with severe renal impairment should use ibandronic acid with caution, as it is primarily excreted by the kidneys. Adequate intake of calcium and vitamin D is recommended during treatment.
